← Leaderboards
Jay Jie Qiang Wu
Vm Discovery, Inc.
$2,132,320
Attributed
$2,132,320
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $498.3K · FY2007–13$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$2,132,320 · 2
By mechanism
R44$2,034,167 · 1
R43$98,153 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Neoplastic”
- David Heimbrook · Leidos Biomedical Research, Inc.$139,710,838
- Michael S. Saag · University Of Alabama At Birmingham$50,288,385
- John Anthony Baron · Dartmouth College$48,910,373
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Bruce W Stillman · Cold Spring Harbor Laboratory$25,455,900
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
Research focus
NeoplasticNaltrexoneEnzyme Inhibitor DrugsLegalLiverMedicalCardiacDrug KineticsHeavy DrinkingLeadCommunicable DiseasesAbstinenceAlcoholismAffectAcamprosateBaseCostAlcoholsAlcohol Use DisorderEnzyme InhibitorsInhibitor/AntagonistIn VivoAdverse EffectsNervous System Structure
Grant awards (6)
Preclinical Development of Selective PKC_epsilon Inhibitors to Treat Alcoholism$463,933
R44 · FY2013 · AA · contact PI
Preclinical Development of Selective PKC_epsilon Inhibitors to Treat Alcoholism$473,919
R44 · FY2012 · AA · contact PI
Preclinical Development of Selective PKC_epsilon Inhibitors to Treat Alcoholism$99,997
R44 · FY2009 · AA · contact PI
Preclinical Development of Selective PKC_epsilon Inhibitors to Treat Alcoholism$498,060
R44 · FY2008 · AA · contact PI
Preclinical Development of Selective PKC_epsilon Inhibitors to Treat Alcoholism$498,258
R44 · FY2007 · AA · contact PI
Multi-Property Design Selective PKC_epsilon Inhibitors$98,153
R43 · FY2004 · AA